Cagrisema 99% High-purity peptides Purity Weight Loss Peptides Cagrilintidefor Overweight or Obesity Adults

  Product Detail  

• I. Basic Properties & Mechanism of Action

  CagriSema is a fixed-dose combination therapy consisting of an amylin analog (cagrilintide) and a GLP-1 receptor agonist (semaglutide), administered via once-weekly subcutaneous injection. Its dual-pathway design integrates complementary metabolic regulation mechanisms:

  • Cagrilintide: Activates amylin and calcitonin receptors (AMYR/CTR), suppressing appetite and delaying gastric emptying.

  • Semaglutide: Enhances insulin secretion, inhibits glucagon release, and synergistically modulates feeding behavior.
    The components demonstrate cooperative action for dual control of energy intake and glucose metabolism .

  ---

  II. Clinical Research Findings

  1. Weight Management

  • Non-diabetic population (REDEFINE-1, n=3,417):
    20.4% mean weight reduction after 68 weeks; 53.6% of participants achieved ≥20% weight loss. Fully adherent subgroup reached 22.7% reduction.

  • Type 2 diabetes population (REDEFINE-2, n=1,206):
    13.7% mean weight loss; 73.5% achieved glycemic target (HbA1c ≤6.5%).

  2. Metabolic Improvements

  • Glycemic control: HbA1c reduction of 2.18% from baseline, significantly exceeding monotherapy outcomes.

  • Additional benefits: Concurrent improvements in blood pressure, lipid profiles, and insulin sensitivity.

  Efficacy Comparison (68-week data)

  Study Population	Weight Reduction	Key Metabolic Outcomes	Trial
  Non-diabetic obesity	20.4%	53.6% achieved ≥20% weight loss	REDEFINE-1
  T2DM with obesity	13.7%	73.5% achieved HbA1c ≤6.5%	REDEFINE-2

  
  

  1. 1. • III. Safety & Tolerability

          • Primary adverse events: Mild-to-moderate gastrointestinal incidents (nausea, vomiting, diarrhea; ~72.5% incidence), predominantly during dose escalation and typically transient.

          • No new safety signals: No clinically significant cardiovascular or neuropsychiatric adverse events observed in trials.

          • Dosing flexibility: Dynamic dose adjustment permitted, with lowest discontinuation rate in class (<5%).

          ---

          IV. Development Status & Research Directions

          1. Indication focus:

             • Core targets: Obesity (BMI≥30) and type 2 diabetes with obesity.

             • Long-term cardiometabolic outcome studies (REDEFINE 3/4) expected 2025.

          2. Competitive assessment:

             • Active head-to-head Phase III trial vs. tirzepatide (n=800; results 2025).

          3. Formulation optimization:

             • Exploring oral (e.g., Amycretin) and monthly injectable formulations to improve adherence.

             • 
               

Mode of transport

Company Profile

FQA 

Certificates